Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 62

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 62
---
Surg1,093 484 1,577 941 470 1,412    Interventional Cardiology Therapies232 465 697 195 457 652    Watchman390 34 425 311 33 344    Cardiac Rhythm Management358 220 578 354 221 575     Electrophysiology511 219 730 158 143 300 Cardiology1,491 938 2,429 1,017 854 1,872 Peripheral Interventions376 280 656 299 274 573 Cardiovascular1,868 1,218 3,085 1,316 1,129 2,445 Total Net Sales$2,960 $1,702 $4,663 $2,258 $1,599 $3,856 Refer to Note J – Segment Reporting for information on our reportable segments.Three Months Ended March 31,Geographic Regions20252024U.S.$2,960 $2,258 Europe, Middle East and Africa846 803 Asia-Pacific701 647 Latin America and Canada155 149 Total Net Sales$4,663 $3,856 Emerging Markets(1)$690 $648 

30

(1) Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.Deferred RevenueContract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $641 million as of March 31, 2025 and $635 million as of December 31, 2024. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $68 million in the first quarter of 2025 that was included in the above contract liability balance as of December 31, 2024. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less